RESUMO
Six cases of vascular lesion associated with percutaneous removal of renal calculi are described. The lesions had been caused during percutaneous access or ultrasound fragmentation of the stone. Those that had resolved spontaneously have not been included. When vascular injury is suspected during the procedure, the appropriate measures must be taken to resolve the different complications, such as arteriovenous, arteriocaliceal or venocaliceal fistula. Since there is little reference to this subject in the Spanish literature, the experience described herein may be of interest to the urologist who has only recently begun to perform this technique.
Assuntos
Complicações Intraoperatórias/terapia , Cálices Renais/cirurgia , Pelve Renal/cirurgia , Nefrostomia Percutânea/efeitos adversos , Artéria Renal/lesões , Veias Renais/lesões , Fístula Arteriovenosa/etiologia , Fístula Arteriovenosa/terapia , Embolização Terapêutica , Feminino , Humanos , Complicações Intraoperatórias/etiologia , Cálculos Renais/complicações , Cálculos Renais/cirurgia , Nefropatias/etiologia , Nefropatias/terapia , Masculino , Pessoa de Meia-Idade , Nefrectomia , Fístula Urinária/etiologia , Fístula Urinária/terapiaRESUMO
This study evaluated the blood pressure effects of administration of once daily oral benazepril hydrochloride, a new angiotensin-converting enzyme (ACE) inhibitor, for mild-to-moderate hypertension. After a 2 to 4 week placebo baseline period, patients with diastolic blood pressure between 95 and 114 mm Hg, were randomized to receive either placebo or benazepril hydrochloride, 5, 10, 20, or 40 mg, once daily in double-blind fashion for 28 days. Blood pressure was measured predose and at 1, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours after the dose during inpatient observation days at the end of the placebo baseline period, and on the first and last day of the double-blind treatment period; and 24 hours after the dose at weekly outpatient visits. All doses of benazepril hydrochloride resulted in clinically important reductions in diastolic and systolic blood pressures that lasted between 12 and 24 hours after both the first dose, and following the last dose after 4 weeks of treatment. The findings indicate that benazepril hydrochloride may be clinically useful as once-daily monotherapy in many patients with hypertension.